Cognetivity Neurosciences (CSE: CGN) is set to benefit from a recent ruling by the Centers for Medicare and Medicaid Services, which has committed to providing coverage for fully approved FDA treatments for Alzheimer’s.
Medicare has agreed to cover drugs that may slow the progression of Alzheimer’s disease on the condition that the physician and clinical team prescribing such drugs also agree to collect real-world evidence of effectiveness through a registry. Prior to the changes announced on June 1, Medicare only covered such treatments for patients involved in clinical trials.
Cognetivity’s flagship product, CognICA, was demonstrated to be effective in tracking cognitive function in real-world settings during treatment for Alzheimer’s in patients using Aduhelm, a drug developed by Biogen, which was approved by the FDA in June 2021.
Sponsored · Silver47 Exploration Inc.
“We are thrilled to be in a unique position to play such a pivotal role in the effective targeting and delivery of newly approved Alzheimer’s drugs in the US. Outstanding sensitivity to early-stage disease – the ability to measure small changes in brain function – and the ability to effectively monitor patient progress are CognICA’s greatest strengths, as demonstrated in thousands of patients and numerous peer-reviewed publications,” commented CEO Sina Habibi.
CognICA is said to have screened hundreds of individuals suspected of mild cognitive impairment, and has accurately identified those who need further assessment. Once diagnosed, the platform can be utilized to monitor changes in cognitive function in patients receiving treatment, providing objective, repeatable, and reliable data on the response to treatment by patients.
“CognICA’s continuously learning AI models allow for this challenge to be solved at scale, which will enable payers and providers to roll out these desperately needed treatments with confidence, and then monitor their effectiveness with unprecedented precision, providing valuable insights for clinicians and contributing to the required real-world evidence for coverage,” continued Habibi.
Cognetivity Neurosciences last traded at $0.305 on the CSE.
Information for this briefing was found via Sedar and the sources mentioned. Canacom Group, the parent company of The Deep Dive, is currently long the equity of Cognetivity Neurosciences. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
